Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...

Paris: Sanofi and Regeneron have announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and ...

Sanofi and Regeneron receives Japanese marketing approval for Dupixent to treat bronchial asthma in children aged 6 to 11 years: Paris Wednesday, December 24, 2025, 11:00 Hrs [IST ...

Depemokimab-ulaa (Exdensur) has been approved by the US FDA as add-on maintenance therapy for severe asthma with an ...

According to the National Center for Health and Statistics, under the Centers for Disease Control and Prevention (CDC), ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

What is Exdensur? A new FDA-approved asthma biologic from GSK that only needs two doses a year for severe eosinophilic asthma ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...

1 Immunology Program, Benaroya Research Institute, Seattle, WA, United States 2 Department of Immunology, University of Washington School of Medicine, Seattle, WA, United States Helminths remain one ...

Regeneron (REGN) and Sanofi (SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing ...

Recognized experts in acute pulmonary care discuss the benefits of pulmonary rehabilitation for patients recovering from CAP, including COVID pneumonia. Air Supply: Targeting Eosinophils in Severe ...

Pittsburgh Steelers veteran Cam Heyward has seen plenty of change over the course of his long NFL career — but strong ...